Ketek is contraindicated in patients with myasthenia gravis. There have been reports of fatal and life-threatening respiratory failure in patients with myasthenia gravis associated with the use of Ketek. (See CONTRAINDICATIONS.)
KETEK tablets contain telithromycin, a semisynthetic antibacterial in the ketolide class for oral administration.
KETEK tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below for patients 18 years old and above.
Acute bacterial exacerbation of chronic bronchitis due to
Streptococcus pneumoniae, Haemophilus influenzae, or
Acute bacterial sinusitis due to
Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, or
Community-acquired pneumonia (of mild to moderate severity) due to
Streptococcus pneumoniae, (including multi-drug resistant isolates [MDRSP * ]),
Haemophilus influenzae, Moraxella catarrhalis, Chlamydophila pneumoniae, or
*MDRSP, Multi-drug resistant
includes isolates known as PRSP (penicillin-resistant
Streptococcus pneumoniae), and are isolates resistant to two or more of the following antibiotics: penicillin, 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of KETEK and other antibacterial drugs, KETEK should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Published Studies Related to Ketek (Telithromycin)
Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone. [2010.01]
The aim of this study is to determine whether the inhibition of CYP2D6 and CYP3A4 enzyme activity with telithromycin affects the pharmacokinetics and pharmacodynamics of orally administered oxycodone in a randomized 2-phase crossover study. Eleven healthy subjects were pretreated with 800 mg of oral telithromycin or placebo for 4 days...
Controlled Trial of a 5-Day Course of Telithromycin versus Doxycycline for Treatment of Mild to Moderate Scrub Typhus. [2007.06]
New antibiotics are required to have the antibacterial activity against doxycycline-resistant Orientia tsutsugamushi. An in vitro sensitivity study showed that telithromycin was more effective than erythromycin for Rickettsia, Bartonella, and Coxiella burnetii... Telithromycin could be considered a promising new antibacterial agent for patients with scrub typhus.
Controlled Trial: 5-day Course of Telithromycin versus Doxycycline for the Treatment of Mild to Moderate Scrub Typhus. [2007.04.02]
New antibiotics are required to have the antibacterial activity against doxycyline-resistant O... Telithromycin could be considered as a promising new antibacterial agent for patients with scrub typhus.
The effect of telithromycin in acute exacerbations of asthma. [2006.04.13]
BACKGROUND: We conducted a double-blind, randomized, placebo-controlled study to evaluate the efficacy of telithromycin in patients with acute exacerbations of asthma... CONCLUSIONS: This study provides evidence of the benefit of telithromycin in patients with acute exacerbations of asthma; the mechanisms of benefit remain unclear. (ClinicalTrials.gov number, NCT00273520.). Copyright 2006 Massachusetts Medical Society.
Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide. [2006.03]
BACKGROUND AND OBJECTIVE: The antidiabetic repaglinide is metabolized by cytochrome P450 (CYP) 2C8 and CYP3A4. Telithromycin, an antimicrobial agent, inhibits CYP3A4 in vitro and in vivo. Montelukast, an antiasthmatic drug, is a potent inhibitor of CYP2C8 in vitro. We studied the effects of telithromycin, montelukast, and the combination of telithromycin and montelukast on the pharmacokinetics and pharmacodynamics of repaglinide... CONCLUSIONS: Telithromycin increases the plasma concentrations and blood glucose-lowering effect of repaglinide by inhibiting its CYP3A4-catalyzed biotransformation and may increase the risk of hypoglycemia. Unexpectedly, montelukast has no significant effect on repaglinide pharmacokinetics, suggesting that it does not significantly inhibit CYP2C8 in vivo. The low free fraction of montelukast in plasma may explain the lack of effect on CYP2C8 in vivo, despite the low in vitro inhibition constant, highlighting the importance of incorporating plasma protein binding to interaction predictions.
Clinical Trials Related to Ketek (Telithromycin)
Japanese Study Evaluating the Effects of Telithromycin in Children With Acute Otitis Media [Completed]
The primary objective is to assess the safety of telithromycin (HMR3647) 20 mg/kg qd for 5
days in children with acute otitis media (AOM).
Secondary objectives are to assess Efficacy, Pharmacokinetics and Acceptability of
telithromycin 20 mg/kg qd for 5 days in children with AOM.
Japanese Study Evaluating the Effects of Telithromycin in Children With Community-Acquired Pneumonia [Completed]
The primary objective is to assess the safety of telithromycin (HMR3647) 20 mg/kg qd for 5-7
days in children with community-acquired pneumonia (CAP).
Secondary objectives are to assess Pharmacokinetics, Efficacy and Acceptability of
telithromycin 20 mg/kg qd for 5-7 days in children with CAP.
TELI TON - Telithromycin in Tonsillitis [Terminated]
This is a multinational, randomized (1: 1), double blind, double dummy, comparator-controlled,
2 parallel treatment group study in subjects from 6 months to < 13 years of age, with
Streptococcus pyogenes tonsillitis/pharyngitis (T/P).Each subject will receive either
telithromycin 25 mg/kg once daily for 5 days or penicillin V, 13. 3 mg/kg three times daily
for 10 days. Matching placebo for telithromycin and penicillin V will also be dispensed for 5
and 10 days respectively, to provide blinding to the different treatment regimens. A positive
rapid identification test for streptococcal Group A antigen will be required for all subjects
at Visit 1 (Day 1) for entry into the study. Throat swab specimens for bacterial culture,
identification, and antibiotic-susceptibility testing will be taken at Visits 1, 3 and 4.
Telithromycin in Respiratory Tract Infections [Completed]
- The primary objective of the study is to evaluate clinical efficacy i. e. to show that
with respect to clinical cure rate, KetekŪ (telithromycin) in the treatment of community
acquired respiratory tract infections: community acquired pneumonia (CAP), acute
bacterial exacerbation of chronic bronchitis (AECB) and acute sinusitis (AS), in
The secondary objectives are to:
- Further assess the efficacy of KetekŪ (telithromycin) by considering the rate at which
additional antibacterials were prescribed to treat the primary infection; the rate of
hospitalisation due to a complication of the primary infection and assessment of
bacteriological data, chest X-ray and sinus X-ray if available.
- Evaluate safety of KetekŪ (telithromycin) through Adverse Event (AE) and Serious Adverse
Event (SAE) reporting
Study Comparing the Clinical Efficacy and Health Outcomes of Outpatients With Mild to Moderate Community-Acquired Pneumonia (CAP) Treated With Either Telithromycin Once Daily for 7 Days, or Azithromycin Once Daily for 5 Days [Completed]
A multinational, multicenter, randomized, double-blind, study in areas of high pneumococcal
resistance comparing the clinical efficacy and health outcomes of outpatients with mild to
moderate Community-Acquired Pneumonia (CAP) treated with either telithromycin once daily for
7 days, or azithromycin once daily for 5 days
Reports of Suspected Ketek (Telithromycin) Side Effects
Stevens-Johnson Syndrome (2),
Confusional State (1),
Rectal Haemorrhage (1),
Drug Interaction (1),
Lactic Acidosis (1),
Tricuspid Valve Incompetence (1),
Diplopia (1), more >>
Page last updated: 2010-10-05